News | December 05, 2023
AstraZeneca discontinues Phase III trials of Stabilizer-CKD and Dialize-Outcomes
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Clinical Trial Data Services supports small to midsize sponsor companies helping them to take the next step towards market approval for their drug or device product.
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
The companies will work with investigators to share the results with the scientific community
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Subscribe To Our Newsletter & Stay Updated
